Related scientific articles (all)

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case.

Authors : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart-Gebhart M
Year : 2014
Journal : Eur. J. Cancer
Volume : 50(18)
Pages : 3089-97

Huisartsen staan machteloos tegenover kanker, Artsenkran

Authors : Awada A
Year : 2014
Journal : Artsenkrant
Volume : 2350
Pages : 90c

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Authors : Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(29)
Pages : 3212-20

International study on inter-reader variability for circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart-Gebhart M, Borgen E, Naume B, Jimenez J, Aura CM, Zorzino L, Cassatella MC, Sandri MT, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K
Year : 2014
Journal : Breast Cancer Res
Volume : 16(2)
Pages : R43

Ras in digestive oncology: from molecular biology to clinical implications.

Authors : Charette N, Vandeputte C, Stärkel P
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(4)
Pages : 454-61

Notwithstanding the fact that no breaking, practice changing studies were presented in the sessions devoted to gynaecological cancers at this years' annual ESMO meeting, the strong trend towards targeted therapies was confirmed, in accordance with th

Authors : Kerger J
Year : 2014
Journal : Belgian J Medical Oncology
Volume : 8(4)
Pages : 147-51

En cancérologie, la médecine personnalisée est en route, Journal du Médecin

Authors : Awada A
Year : 2014
Journal : Journal du médecin.
Volume : 2352
Pages : 32

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors.

Authors : Sonnenblick A, Fumagalli D, Azim HA, Sotiriou C, Piccart-Gebhart M
Year : 2014
Journal : Clin Cancer Res
Volume : 20(24)
Pages : 6242-6

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.

Authors : Mokrim M, Aftimos P, Errihani H, Piccart-Gebhart M
Year : 2014
Journal : BMJ Case Rep
Volume : 2014(null)

Cardiac metastase of a soft tissue sarcoma: a case report and a review of the literature.

Authors : Polastro L, de Saint-Aubain de Somerhausen N, Lemort M, Delhaye F, Awada A
Year : 2014
Journal : Rev Med Brux
Volume : 35(6)
Pages : 499-503

The AURORA initiative for metastatic breast cancer.

Authors : Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, Von Minckwitz G, Gelber Rd, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart-Gebhart M
Year : 2014
Journal : Br J Cancer
Volume : 111(10)
Pages : 1881-7

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Authors : Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart-Gebhart M, Vobecky N, Thuresson M, Flamen P
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 145(2)
Pages : 411-8

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Authors : Piccart-Gebhart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J
Year : 2014
Journal : Ann Oncol
Volume : 25(12)
Pages : 2357-62

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee.

Authors : Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V
Year : 2014
Journal : Lung Cancer
Volume : 85(1)
Pages : 74-80

Thrombo-embolic events in cancer patients with impaired renal function

Authors : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Year : 2014
Journal : J Strength Cond Res
Volume : 5(4)
Pages : 202

Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria.

Authors : Klastersky J, Georgala A
Year : 2014
Journal : Crit Rev Oncol Hematol
Volume : 92(3)
Pages : 266-78

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Authors : Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart-Gebhart M, de Azambuja E, Loi S
Year : 2014
Journal : Breast
Volume : 23(4)
Pages : 473-81

Foreword for the edition of Treatment Strategies

Authors : Awada A, Aftimos P
Year : 2014
Journal : Oncology
Volume : 4(1)
Pages : 9

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Authors : Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, de Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, Van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L
Year : 2014
Journal : Eur. J. Cancer
Volume : 50(17)
Pages : 2983-93

Impact of tumor sequencing on the use of anticancer drugs.

Authors : Thomas F, Desmedt C, Aftimos P, Awada A
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(3)
Pages : 347-56